DexCom, Inc. · NASDAQ:DXCM

DexCom — Investor Presentation (October 2023)

25 slides from DexCom's investor presentation, October 2023

  1. Slide 1: Dexcom Investor Presentation October 2023

    Dexcom Investor Presentation October 2023 CONFIDENTIAL – DO NOT DISTRIBUTE

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains “forward” looking statements that are based on our management’s beliefs and assumptions and on information currently available to management. We intend for such forward-looking statements to be covered by the safe harbor provisions for forward-looking

  3. Slide 3: Our Mission: Empowering people to take control of health

    Our Mission: Empowering people to take control of health 3

  4. Slide 4: 2023 Outlook as of October 26, 2023

    2023 Outlook as of October 26, 2023 Objectives & FY23 Guidance Considerations Revenue of $3.575 – 3.600 billion • Global rollout of G7 (~23 – 24% Growth) • Expansion of Dexcom ONE into new geographies • Building momentum in type 2 basal Gross Margin of ~64% • Strong year-over-year operating expense

  5. Slide 5: A Global Crisis that Remains Uncontrolled

    A Global Crisis that Remains Uncontrolled Diabetes Diagnosis and Cost Global Diabetes Related Adults (aged 20-79) with Diabetes Globally Health Expenditures 783m in 2045E USD USD 537m in 2021 463m 2019 2021 in 2019 151m in 2000 Past 2 Years Source: IDF Atlas, 10th edition (2021) 5

  6. Slide 6: Intermittent glucose monitoring is not enough for intensive insulin management

    Glucose (mg/dl) 340 SMBG* 320 300 280 260 Intermittent 240 220 glucose monitoring 200 180 is not enough for 160 140 intensive insulin 120 100 Target Glucose Range management… 80 60 40 20 0 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (hours) *As compared to Self Monitoring of Blood Glucose (SMBG) 6

  7. Slide 7: Intermittent glucose monitoring is not enough for intensive insulin management

    Glucose (mg/dl) 340 320 300 OVER 4 HOURS ABOVE 280 210 BEFORE SMBG* 260 Intermittent 240 220 ABOVE 140 FOR glucose monitoring 200 180 13.5 HOURS is not enough for 160 140 intensive insulin 120 100 Target Glucose Range management… 80 60 DANGEROUS LOW 40 FOR 1 HOUR 20 0 0 2 4 6 8 10 12 14 16 18 20 22

  8. Slide 8: ...and non-intensive type 2 diabetes management

    Glucose (mg/dl) 340 SMBG* 320 300 280 260 240 220 …and non-intensive 200 180 type 2 diabetes 160 140 management 120 100 Target Glucose Range 80 60 40 20 0 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (hours) *As compared to Self Monitoring of Blood Glucose (SMBG). 8

  9. Slide 9: ...and non-intensive type 2 diabetes management

    Glucose (mg/dl) 340 320 300 280 260 APPROXIMATELY 17 HOURS ABOVE TARGET RANGE, INCLUDING 240 ~6 HOURS IN SEVERE HYPERGLYCEMIA (>250 mg/dl) 220 …and non-intensive 200 180 AVG GLUCOSE: 185 mg/dl type 2 diabetes 160 140 management 120 100 Target Glucose Range 80 60 40 20 0 0 2 4 6 8 10 12 14 16 18 20 2

  10. Slide 10: We can do more

    We can do more pexcom 10

  11. Slide 11: Connectivity as a Competitive Advantage

    Connectivity as a Competitive Advantage Differentiating through hardware and software Customers Automated Insulin Delivery Connected Pen Digital Health Apps Loved Ones Follow App Healthcare Providers Clarity Clinic 11

  12. Slide 12: G7 is the new standard in CGM technology

    is the new standard in CGM technology Most Accurate1 Incredible Simplicity Engaging 1. Dexcom, data on file, 2023.

  13. Slide 13: G7 Is Living up to its High Expectations

    G7 Is Living up to its High Expectations DIRECT FEEDBACK For me, it is definitely a big I basically forgot it was there… step forward in terms of that is the dream, really. comfort and convenience. We are obsessed with how Once it was on and in, I didn’t quickly the sensors warm up, know it was ther

  14. Slide 14: What's Next for G7?

    What’s Next for G7? International Building Expanding Connected Markets Access Solutions Extending launch to additional Established reimbursement for G7 in US Leveraging world’s most connected CGM geographies: across our channels ecosystem1 to bring more choice to users • We are fully launched in 16

  15. Slide 15: Core US Market

    Insulin & Non-Insulin Hypoglycemia Population All Insulin ~7m Core US Market IIT ~4m Momentum and opportunity remain significant With coverage for basal insulin users and problematic Estimated US IIT CGM Users – All companies* Estimated Reimbursed Population* hypoglycemia there is more people with a

  16. Slide 16: Commercial Access Efforts Empower our Customers

    Commercial Access Efforts Empower our Customers Meeting our customers where they want to be met in either the pharmacy or durable medical equipment channels Simple to Prescribe Broad Customer Access Efficient Service Model Dexcom is the number one covered and most reimbursed CGM on the market1 1. Ma

  17. Slide 17: Commercial Execution

    Commercial Execution Growing presence within primary care STRATEGIC INITIATIVES Drove reimbursement through 01 clinical evidence (MOBILE study) Over the past two years1: 02 Doubled size of sales force in 2021 We doubled total primary care prescriber Introduced sampling program base 03 to highlight t

  18. Slide 18: Gaining Market Share Internationally

    Gaining Market Share Internationally Entering new geographies Reducing administrative barriers Gaining reimbursement Well-positioned to extend growth Leveraging e-commerce platform momentum OUS Going direct in strategic markets 18

  19. Slide 19: Dexcom's Portfolio Strategy: Meeting the Needs of Each Market

    Dexcom’s Portfolio Strategy: Meeting the Needs of Each Market Broad Limited Tiered Reimbursement Markets Reimbursement Reimbursement G-Series G-Series Dexcom ONE Dexcom ONE • Leading Accuracy • Connected & Higher- • Simple & Accurate • E-Commerce & Connectivity Risk Populations Accessibility 19

  20. Slide 20: OUS Markets

    Access for over 4 million additional people with diabetes over the past 2+ years OUS Markets Significantly improving access We have successfully expanded coverage for G-Series and Dexcom ONE *Estimated Reimbursed Population based on Dexcom market research. 20

  21. Slide 21: Type 2 Diabetes: 3 Elements of an Effective Solution

    User Engagement Health Outcomes Type 2 Diabetes 3 Elements of an Return on Investment Effective Solution 21

  22. Slide 22: Type 2 Diabetes: 3 Elements of an Effective Solution

    Type 2 Diabetes: 3 Elements of an Effective Solution User Engagement Health Outcomes Return on Investment Sustained engagement demonstrated Evidence generation through clinical Strong economic return to payers in non-intensive studies trials, real-world evidence, and pilots with key partners Example

  23. Slide 23: Across All Segments of T2D, CGM Use Increases with GLP-1 Initiation

    Across All Segments of T2D, CGM Use Increases with GLP-1 Initiation % CGM usage for those initiating GLP-1 therapy CLINICAL DRIVERS OF CGM in each year USE WITH GLP-1 40.0% Type 2 – Intensive Insulin 30.0% Average CGM Increase: 2.0x Provides insights and behavior 20.0% modification required for long

  24. Slide 24: Empowering people to take control of health

    Our Mission: Empowering people to take control of health Where We Are Where We Are Going • Type 1 • Type 2 Non-Insulin • Type 2 IIT • Pre-Diabetes • Type 2 Basal-Only • Gestational Diabetes • Type 2 Problematic • Patient Monitoring Hypo (Non-Insulin) • Health & Wellness 24

  25. Slide 25: This is our WHY

    This is our WHY 25

Dexcom — Investor Presentation (October 2023) on 6ix